COSM: Cosmos Health subsidiary wins 253,657-unit contract manufacturing orders

AI Summary

Cosmos Health (NASDAQ: COSM) said its Cana Laboratories unit received contract manufacturing orders from Nassington and Verisfield totaling 253,657 units for a mix of products including Gritse oral solutions, Gritse forte, Fungofort spray, Paco-4 tablets, dexamethasone oral solutions, and Foproct rectal cream. The work will be performed at Cana, which operates under EU GMP/EMA certification, representing non-dilutive manufacturing revenue and deeper partner relationships, though the release gave no pricing, delivery schedule, or estimated revenue impact.

Positives

Combined orders total 253,657 units across multiple pharmaceutical products
Orders come from two external partners (Nassington and Verisfield), showing third-party demand
Manufacturing to be done at Cana Laboratories, which is EU GMP/EMA certified

Negatives

No dollar value, margins, or expected revenue impact disclosed
No delivery timeline or contract duration provided
Release does not indicate whether orders are one-time or recurring